Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAI-9531 Oral
- Development stage
- Preclinical
- Lead developer
- Kailera Therapeutics
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
KAI-9531 Oral is a GLP-1/GIP receptor dual agonist formulated as a once-daily oral tablet. It is being developed by Kailera Therapeutics for the treatment of obesity and type 2 diabetes. This oral formulation is part of Kailera's diversified pipeline of next-generation therapies for weight management.
02
Targets
GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)
Beyond the preview
Go deeper on KAI-9531 Oral.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAI-9531 Oral.